Metastases Directed Therapy for Oligometastatic Breast Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-70
SponsorNational Cancer Institute, Egypt
About this trial
This is a phase III randomized study evaluating the benefit from adding metastases directed therapy and locoregional treatment of the primary in breast cancer patients diagnosed with de novo oligometastatic disease patients will be randomized to receive the standard of care (SOC) treatment vs. systemic treatment + Stereotactic Ablative Radiation Therapy. Responders will be randomized to either undergo loco-regional management of the primary tumor or not
Eligibility criteria
Qualifiers
Female patients aged 18 to 70 years.
Pathological evidence of breast cancer, any grade, any T stage.
Radiological (at least) evidence of metastatic activity with maximum number of 5 extracranial lesions.
Performance status ≤ 2
Disqualifiers
Prior radiotherapy to affected site(s) in less than a year.
Active Connective tissue diseases (e.g Rheumatoid Arthritis).
Progression to widespread metastatic disease
Cases with brain metastasis
Trial design
Treatments tested in this trial
- Stereotactic Ablative Radiation Therapy
- Locoregional treatment
- Standard of Care
Treatment groups
150 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov